Purpose Black women often experience poorer breast cancer-related outcomes and higher
mortality than white women. A contributor to this disparity may relate to the disproportionate …

Purpose The late cardiac effects of adjuvant anthracycline therapy in survivors of early-stage
breast cancer have had limited study. Subclinical and clinical cardiac late effects may …

Background Precision medicine is heralded as offering more effective treatments to smaller
targeted patient populations. In breast cancer, adjuvant chemotherapy is standard for …

Background Cardiac toxicity from anthracyclines (ACH) can lead to therapy discontinuation,
hospitalization or congestive heart failure (CHF). Since such risk may vary by patient, we …

Abstract Background Assessment of 2D/3D left ventricular ejection fraction (LVEF) and 2D
global longitudinal strain (GLS) is the gold standard for diagnosing cancer therapeutics …

More than 80% of children and 60% of adults with cancer will become long-term survivors,
emphasizing the importance of late effects of cancer therapy. Cardiotoxicity due to …

Background/aim Cardiotoxicity is a potential complication of anticancer therapy. While
guidelines have been developed to assist practitioners, an effective, evidence based clinical …

Background Epirubicin-based chemotherapy improves the outcome of early breast cancer
(BC) patients. However, cardiotoxicity remains an important side effect. Methods We re …

Anthracyclines are among the most active agents for the treatment of breast cancer; their use
in combination regimens improves both disease-free and overall survival in patients with …

While the number of cancer patients is increasing with the arrival of the super-aging society,
the age-adjusted mortality rate of cancer decreases due to medical advances, and the …